

# Table of CONTENTS

Message from CEO	1
Message from Director	2
Cancer Registry 2015 : Abstract	3
Annual Cancer Registry 2015	4
<i>The Top 10 Leading Site of Cancer, Distribution of All Cancer by Age and Gender, Patient Category, Method of Diagnosis, Staging, Type of Treatment, Patient Follow up, Patient Nationality, The Top 10 Leading Site of Thai Patient Cancer, The Top 10 Leading Site of Non-Thai Patient Cancer</i>	
Review of Breast Cancer	17
Review of Colorectal Cancer	22
Review of Lung Cancer	27
Review of Liver & Hepatobiliary Cancer	32
Review of Head & Neck Cancer	40
Hematologic Malignancies 2015	46
Age Distribution in All Male Cancer Number of Case	62
Age Distribution in All Female Cancer Number of Case	64
Breast Cancer Survival	67
Colorectal Cancer Survival	69
Lung Cancer Survival	72
Cancer Registry Team	75



# Message from CEO

Cancer is the major cause of death in the world and also Thailand. There are many factors that contribute to cancer such as environment, pollution, diet and obesity, infection, radiation, physical agents and hormones, etc.

Therefore, people nowadays pay attention to not only best treatment but also cancer prevention. Global Healthcare organizations are focusing to develop and improve the method to provide more comprehensive preventive treatment and even medication and technology in order to succeed for treatment and prevention.

As part of BDMS network, Wattanosoth Hospital is focusing on cancer care which provides the best treatment to cancer patients and preventive guidelines with world class standard.

The 2017 Cancer Registry Year Book has been carefully produced by Wattanosoth Hospital to general public with the newest most up-to-date research on cancer. We hope the book will be beneficial to all readers.



*Poram Prasarttong-Osoth*

Poramaporn Prasarttong-Osoth, M.D. FRCS (Glas)  
CEO - Group 1, BDMS

# Message from Director



Now it comes to the first decade of The Cancer Registry by Wattanosoth Cancer Hospital. We commit to provide an accurate cancer registry annually for readers to have more understanding and knowledge that can be practically used for a better cancer treatment.

The data are collected, stored, managed and analyzed by the cancer registrars who are trained to collect accurate, complete and timely data. The data is reported as an information resource for research and public organizations. Cancer registry is provided for readers to learn more about the causes of cancer to be able to diagnosis or detect it earlier.

On behalf of Wattanosoth Cancer Hospital, we are looking forward to be an excellent center of cancer care and this cancer registry would be a part of this excellence. We are appreciated and would like to celebrate for the 10<sup>th</sup> of the cancer registry 2015.

Thiravud Khuhaprema, M.D., FRCST., FICS., Visiting Professor  
Hospital Director, Wattanosoth Cancer Hospital  
Bangkok Hospital Headquarter

# Cancer Registry 2015 : Abstract

The total of new cases diagnosed as a malignancy at Bangkok Hospital Headquarter (BHQ) is 2027 cases (Tumor registry is 1868 cases and Hematologic malignant is 159 cases). There was a little bit decrease in the total number as compared to 2055 cases in 2014.

The sex ratio is 1:1. This age distribution has not changed since the year 2014. Patients who are between 50-69 y/o are the majority accounting for more than half of the total. The average age in male patients is 60-64 y/o which is slightly older than the female age of 55-59 y/o.

The Top 5 malignancies are:

- |   |   |
|---|---|
| 1) Breast (Included DCIS) - 21.71 percent | 2) Colorectal - 10.85 percent           |
| 3) Lung - 10.11 percent                   | 4) Liver & Hepatobiliary - 7.40 percent |
| 5) Head & Neck - 5.77 percent             |   |

The trend for the top 5 malignancies has not changed over the past 9 years (2006-2014). For the past 9 years the top 5 have been: Breast, Colorectal, Lung, Liver & Hepatobiliary and Head & Neck cancer. However, when compared to last year, the overall number of cases in Breast cancer decreased significantly by 8.71 percent, Colorectal cancer increased by 0.45 percent, Lung cancer increased by 0.98 percent, Liver & Hepatobiliary decreased by 1.96 percent and Head & Neck cancer decreased by 15.82 percent.

The results of overall staging of patients who received treatment at Bangkok Hospital Headquarter (BHQ) are: Stage 0 is 1.83 percent, Stage I is 25.81 percent, Stage II is 18.60 percent, Stage III is 22.87 percent, and Stage IV is 21.54 percent. Unspecified stage (due to lack of pertinent information) is 7.72 percent. And in cases of Brain cancer has no stage grouping applies in AJCC Staging manual is 1.63 percent. All results are similar to 2014 staging results.

Analysis of the primary treatments modalities indicates that surgery continues to be the majority (24 percent), followed by Radiation therapy (15 percent), Chemotherapy (4 percent) and Concurrent chemo-radiation (3 percent) and Intervention treatment (3 percent)

Patients who are still living after diagnosis or treatment in 2015 is 36 percent, patients alive without disease are 20 percent, and patients who have died with cancer as the cause are 3 percent. At this time no patients receiving treatment have been lost to follow-up.

Ratio of Thai to non-Thai patients is 1:1 in year 2015 equal to the year 2014. The top 5 rankings of non-Thai patients are: Myanmar, Bangladesh, United Arab Emirates, Cambodia and Ethiopia, respectively.

The Top 5 malignancies of Thai patients are:

- |   |                               |
|---|-------------------------------|
| 1) Breast (Included DCIS) - 27.09 percent | 2) Colorectal - 11.97 percent |
| 3) Lung - 10.45 percent                   | 4) Head & Neck - 5.98 percent |
| 5) Prostate - 5.66 percent                |                               |

The Top 5 malignancies of non-Thai patients are:

- |   |   |
|---|---|
| 1) Breast (Included DCIS) - 17.24 percent | 2) Colorectal - 9.93 percent            |
| 3) Lung - 9.84 percent                    | 4) Liver & Hepatobiliary - 9.30 percent |
| 5) Head & Neck - 5.60 percent             |   |


It is the fifth time BHQ can follow the patients for 5 years and report the 5 years survival. We have shown and discussed the data of those survivors of top 3 cancers which are breast, colorectal and lung in separated chapters.

# WATTANOSOTH ANNUAL CANCER REGISTRY 2015


## THE TOP 10 LEADING SITE OF CANCER IN BANGKOK HOSPITAL HEADQUARTER

Code	Primary site	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
C50, D05	Breast (included DCIS)	2	0.21	438	40.59	440	21.71
C18-C20	Colorectal	133	14.03	87	8.06	220	10.85
C34	Lung	130	13.71	75	6.95	205	10.11
C22-C24	Liver & Hepatobiliary	105	11.08	45	4.17	150	7.40
C01-C14	Head & Neck	84	8.86	33	3.06	117	5.77
C61	Prostate	112	11.81	0	0.00	112	5.53
C81-C85	Lymphoma	63	6.65	26	2.41	89	4.39
C73	Thyroid gland	26	2.74	57	5.28	83	4.09
C44	Skin	49	5.17	19	1.76	68	3.35
C53	Cervix	0	0.00	64	5.93	64	3.16


## TOP 10 CANCER FOR ALL GENDER



## TOP 10 CANCER IN MALE




## TOP 10 CANCER IN FEMALE



## DISTRIBUTION OF ALL CANCER BY AGE AND GENDER (EXCLUDED HEMATOLOGIC MALIGNANCIES)

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	1	0.10	1	0.05
05 - 09	2	0.24	2	0.19	4	0.21
10 - 14	1	0.12	0	0.00	1	0.05
15 - 19	2	0.24	2	0.19	4	0.21
20 - 24	6	0.72	5	0.48	11	0.59
25 - 29	7	0.84	23	2.23	30	1.61
30 - 34	10	1.19	32	3.10	42	2.25
35 - 39	28	3.35	56	5.43	84	4.50
40 - 44	39	4.66	91	8.83	130	6.96
45 - 49	46	5.50	132	12.80	178	9.53
50 - 54	73	8.72	147	14.26	220	11.78
55 - 59	86	10.27	162	15.71	248	13.28
60 - 64	142	16.97	120	11.64	262	14.03
65 - 69	126	15.05	92	8.92	218	11.67
70 - 74	109	13.02	68	6.60	177	9.48
75 - 79	74	8.84	47	4.56	121	6.48
80 - 84	57	6.81	25	2.42	82	4.39
85 - 89	21	2.51	16	1.55	37	1.98
90 - 94	6	0.72	8	0.78	14	0.75
95 +	2	0.24	2	0.19	4	0.21
<b>Total</b>	<b>837</b>	<b>100.00</b>	<b>1,031</b>	<b>100.00</b>	<b>1,868</b>	<b>100</b>

## PATIENT CATEGORY OF ALL CANCER IN BANGKOK HOSPITAL HEADQUARTER




Dx. = Diagnosis for Cancer (Dx. by Pathology, Cytology or Imaging)

Rx. = Treatment

Here = Within Bangkok Hospital Headquarter


Other = Outside Bangkok Hospital Headquarter

## METHOD OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



Other = Previously diagnosed as Cancer from other Hospital but no documentation of diagnosis


2014



## STAGING

(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

### All Gender




Stage 0 = Carcinoma in situ


Non stage = In case of CA Brain

Unspecified stage = Incomplete staging due to insufficient patient information

### Male



### Female




## TYPE OF TREATMENT

Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR.only	113	13.50	141	13.68	254	13.60
RT only	122	14.58	133	12.90	255	13.65
Brachytherapy	1	0.12	8	0.78	9	0.48
CT only	30	3.58	30	2.91	60	3.21
Targeted therapy	4	0.48	5	0.48	9	0.48
Hormonal therapy	2	0.24	4	0.39	6	0.32
Intervention	31	3.70	14	1.36	45	2.41
Nuclear medicine	6	0.72	17	1.65	23	1.23
Concurrent chemoradiation	22	2.63	17	1.65	39	2.09
SUR.+RT	17	2.03	12	1.16	29	1.55
SUR.+Brachytherapy	0	0.00	1	0.10	1	0.05
SUR.+CT	19	2.27	37	3.59	56	3.00
SUR.+Im	2	0.24	0	0.00	2	0.11
SUR.+H	0	0.00	25	2.42	25	1.34
SUR.+T	1	0.12	0	0.00	1	0.05
SUR.+I	2	0.24	0	0.00	2	0.11
SUR.+N	5	0.60	9	0.87	14	0.75
SUR.+Concurrent CT-RT	16	1.91	3	0.29	19	1.02
SUR.+Concurrent+T	1	0.12	0	0.00	1	0.05
SUR.+RT+Concurrent CT-RT	1	0.12	0	0.00	1	0.05
RT+Brachytherapy	0	0.00	11	1.07	11	0.59
RT+Concurrent CT-RT	2	0.24	1	0.10	3	0.16
CT+Concurrent CT-RT	1	0.12	3	0.29	4	0.21
RT+T	1	0.12	5	0.48	6	0.32
RT+CT	6	0.72	5	0.48	11	0.59
RT+CT+H	0	0.00	2	0.19	2	0.11
RT+CT+T	1	0.12	0	0.00	1	0.05
RT+CT+Im	1	0.12	0	0.00	1	0.05
RT+H	6	0.72	6	0.58	12	0.64
RT+I	2	0.24	0	0.00	2	0.11
CT+I	1	0.12	0	0.00	1	0.05
CT+T	1	0.12	0	0.00	1	0.05
CT+H	0	0.00	2	0.19	2	0.11
I+T	3	0.36	0	0.00	3	0.16
Concurrent CT-RT+Brachytherapy	0	0.00	7	0.68	7	0.37
Concurrent CT-RT+Brachytherapy+CT	0	0.00	1	0.10	1	0.05
SUR.+RT+CT	4	0.48	10	0.97	14	0.75
SUR.+RT+H	2	0.24	22	2.13	24	1.28


Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR.+CT+I	1	0.12	0	0.00	1	0.05
SUR.+CT+T	0	0.00	1	0.10	1	0.05
SUR.+CT+H	0	0.00	7	0.68	7	0.37
SUR+RT+Brachytherapy	0	0.00	2	0.19	2	0.11
SUR.+RT+CT+T	0	0.00	1	0.10	1	0.05
SUR.+RT+CT+H	0	0.00	10	0.97	10	0.54
SUR.+RT+CT+H+T	0	0.00	1	0.10	1	0.05
RT+Brachytherapy+CT	0	0.00	1	0.10	1	0.05
SUR.+CT+Concurrent CT-RT	1	0.12	2	0.19	3	0.16
Investigation	116	13.86	109	10.57	225	12.04
Supportive	3	0.36	0	0.00	3	0.16
PET/CT	83	9.92	105	10.18	188	10.06
Bone scan	51	6.09	48	4.66	99	5.30
Follow-up	0	0.00	4	0.39	4	0.21
2 <sup>nd</sup> Opinion	156	18.64	208	20.17	364	19.49
MUGA scan	0	0.00	1	0.10	1	0.05
<b>Total</b>	<b>837</b>	<b>100.00</b>	<b>1,031</b>	<b>100.00</b>	<b>1,868</b>	<b>100.00</b>

SUR. = Surgery  
RT = External radiation therapy  
CT = Chemotherapy  
H (Hormone) = Hormonal therapy  
T = Targeted therapy  
I = Intervention  
Im = Immunotherapy

### TYPE OF PRIMARY MANAGEMENT (ALL PATIENT)




### PATIENT FOLLOW UP



2<sup>nd</sup> Opinion only = Intend not to continue diagnosis or treatment at BMC

## REFERRING HOSPITAL



BGH = Consult from Bangkok general hospital

BGH only = Not consult from Bangkok general hospital

SVH = SAMITIVEJ SUKHUMVIT HOSPITAL

BNH = BNH HOSPITAL

Paolo Group = Paolo memorial hospital Group

SSH = SAMITIVEJ SRIRACHA HOSPITAL

BHN = BANGKOK HOSPITAL HUAHIN

BMCO Myanmar = BANGKOK HOSPITAL OFFICE, MYANMAR

BHH = BANGKOK HOSPITAL HATYAI

Siriroj Hos. = PHUKET INTERNATIONAL HOSPITAL

BPL = BANGKOK HOSPITAL PHITSANULOK

BTH = BANGKOK HOSPITAL TRAT

BCM = BANGKOK HOSPITAL CHIANGMAI

WSH only = WATTANOSOTH HOSPITAL

PYT Group = Phyathai hospital Group

BPH = BANGKOK HOSPITAL PATTAYA

SNH = SAMITIVEJ SRINAKARIN HOSPITAL

BPK = BANGKOK HOSPITAL PHUKET

BRH = BANGKOK HOSPITAL RAYONG

BKH = BANGKOK HOSPITAL RATCHASIMA

BCH = BANGKOK HOSPITAL CHANTHABURI


BKN = BANGKOK HOSPITAL KHON KAEN

BPD = BANGKOK HOSPITAL PRAPRADAENG

BSH = BANGKOK HOSPITAL SAMUI

RPH = ROYAL PHNOM PENH HOSPITAL


## PATIENT NATIONALITY



## THE TOP 10 LEADING SITE OF THAI PATIENT CANCER IN BANGKOK HOSPITAL HEADQUARTER


Primary site	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Breast (included DCIS)	1	0.27	248	45.76	249	27.09
Colorectal	66	17.51	44	8.12	110	11.97
Lung	56	14.85	40	7.38	96	10.45
Head & Neck	39	10.34	16	2.95	55	5.98
Prostate	52	13.79	0	0.00	52	5.66
Liver & Hepatobiliary	34	9.02	13	2.40	47	5.11
Cervix	0	0.00	36	6.64	36	3.92
Lymphoma	21	5.57	14	2.58	35	3.81
Endometrium	0	0.00	29	5.35	29	3.16
Thyroid gland	11	2.92	16	2.95	27	2.94

## TOP 10 CANCER FOR THAI PATIENT ALL GENDER




OVERALL CANCER


2014



### TOP 10 CANCER OF THAI PATIENT IN MALE




### TOP 10 CANCER OF THAI PATIENT IN FEMALE



### THE TOP 10 LEADING SITE OF NON-THAI PATIENT CANCER IN BANGKOK HOSPITAL HEADQUARTER


Primary site	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Breast (included DCIS)	1	0.18	190	35.38	191	17.24
Colorectal	67	11.73	43	7.82	110	9.93
Lung	74	12.96	35	6.52	109	9.84
Liver & Hepatobiliary	71	12.43	32	5.96	103	9.30
Head & Neck	45	7.88	17	3.17	62	5.60
Prostate	60	10.51	0	0.00	60	5.42
Thyroid gland	15	2.63	41	7.64	56	5.05
Lymphoma	42	7.36	12	2.23	54	4.87
Skin	40	7.01	6	1.12	46	4.15
Stomach	24	4.20	16	2.98	40	3.61

### TOP 10 CANCER OF NON-THAI PATIENT ALL GENDER






## TOP 10 CANCER OF NON-THAI PATIENT IN MALE



## TOP 10 CANCER OF NON-THAI PATIENT IN FEMALE



## BREAST CANCER


Tumor site	Number	
50.0	Nipple	10
50.1	Central portion of breast	3
50.2	Upper-inner quadrant of breast	36
50.3	Lower-inner quadrant of breast	18
50.4	Upper-outer quadrant of breast	111
50.5	Lower-outer quadrant of breast	18
50.8	Overlapping lesion of breast	11
50.9	Breast, NOS	233
<b>Total</b>		<b>440</b>

Pathology Report	Number	
8000/3	Malignant neoplasm	105
8010/3	Carcinoma, NOS	3
8050/2	Papillary carcinoma in situ	1
8050/3	Papillary carcinoma, NOS	4
8140/3	Adenocarcinoma, NOS	2
8201/3	Cribriform carcinoma, NOS	1
8211/3	Tubular carcinoma, NOS	1
8401/3	Apocrine adenocarcinoma	1
8480/3	Mucinous carcinoma	5
8500/2	Ductal carcinoma in situ	28
8500/3	Invasive ductal carcinoma	272
8507/3	Intraductal micropapillary carcinoma	1
8520/3	Lobular carcinoma	12
8523/3	Invasive duct mixed with other type of carcinoma	1
8573/3	Carcinoma with apocrine metaplasia	1
9020/3	Malignant phyllodes tumor	2
<b>Total</b>		<b>440</b>

## AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	0	0.00	0	0.00
05 - 09	0	0.00	0	0.00	0	0.00
10 - 14	0	0.00	0	0.00	0	0.00
15 - 19	0	0.00	0	0.00	0	0.00
20 - 24	0	0.00	0	0.00	0	0.00
25 - 29	0	0.00	3	0.68	3	0.68
30 - 34	0	0.00	6	1.37	6	1.36
35 - 39	0	0.00	24	5.48	24	5.45
40 - 44	0	0.00	50	11.42	50	11.36
45 - 49	0	0.00	79	18.04	79	17.95
50 - 54	1	50.00	77	17.58	78	17.73
55 - 59	0	0.00	76	17.35	76	17.27
60 - 64	0	0.00	54	12.33	54	12.27
65 - 69	0	0.00	33	7.53	33	7.50
70 - 74	0	0.00	21	4.79	21	4.77
75 - 79	0	0.00	9	2.05	9	2.05
80 - 84	1	50.00	1	0.23	2	0.45
85 - 89	0	0.00	5	1.14	5	1.14
90 - 94	0	0.00	0	0.00	0	0.00
95 +	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>2</b>	<b>100.00</b>	<b>438</b>	<b>100.00</b>	<b>440</b>	<b>100.00</b>

■ Male ■ Female



## METHOD OF DIAGNOSIS


(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Biochemical	0	0.00	0	0.00	0	0.00
Other	0	0.00	12	5.04	12	5.04
Cytology	0	0.00	0	0.00	0	0.00
Histology	0	0.00	226	94.96	226	94.96
Imaging	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>0</b>	<b>0.00</b>	<b>238</b>	<b>100.00</b>	<b>238</b>	<b>100.00</b>

Other = Previously diagnosed as Breast cancer from other Hospital but no documentation of diagnosis

## STAGING

(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)




Unspecified stage = Incomplete staging due to insufficient patient information

## TYPE OF TREATMENT

(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)


Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR.only	0	0.00	53	22.27	53	22.27
RT only	0	0.00	67	28.15	67	28.15
CT only	0	0.00	8	3.36	8	3.36
Hormonal therapy	0	0.00	4	1.68	4	1.68
SUR.+RT	0	0.00	4	1.68	4	1.68
SUR.+CT	0	0.00	15	6.30	15	6.30
SUR.+H	0	0.00	25	10.50	25	10.50
RT+CT	0	0.00	3	1.26	3	1.26
RT+H	0	0.00	6	2.52	6	2.52
CT+H	0	0.00	2	0.84	2	0.84
RT+CT+H	0	0.00	2	0.84	2	0.84
SUR.+RT+CT	0	0.00	7	2.94	7	2.94
SUR.+RT+H	0	0.00	22	9.24	22	9.24
SUR.+CT+T	0	0.00	1	0.42	1	0.42
SUR.+CT+H	0	0.00	7	2.94	7	2.94
SUR.+RT+CT+T	0	0.00	1	0.42	1	0.42
SUR.+RT+CT+H	0	0.00	10	4.20	10	4.20
SUR.+RT+CT+T+H	0	0.00	1	0.42	1	0.42
<b>Total</b>	<b>0</b>	<b>0.00</b>	<b>238</b>	<b>100.00</b>	<b>238</b>	<b>100.00</b>



SUR. = Surgery  
 CT = Chemotherapy  
 T = Targeted therapy  
 RT = External radiation therapy  
 H (Hormone) = Hormonal therapy

## FOLLOW UP STATUS

(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



## COLORECTAL CANCER


Tumor site		Number
C18.0	Cecum colon	5
C18.0	Appendix	4
C18.2	Ascending colon	11
C18.3	Hepatic flexure of colon	6
C18.4	Transverse colon	8
C18.5	Splenic flexure of colon	2
C18.6	Descending colon	7
C18.7	Sigmoid colon	40
C18.9	Colon, NOS	34
C19.9	Rectosigmoid colon	22
C20.9	Rectum	81
<b>Total</b>		<b>220</b>

Pathology Report		Number
M8000/3	Malignant neoplasm	48
M814/3	Adenocarcinoma	153
M8246/3	Neuroendocrine carcinoma, NOS	2
M8480/3	Mucinous adenocarcinoma	11
M8481/3	Mucin producing adenocarcinoma	1
M8490/3	Adenocarcinoma signet ring cell type	5
<b>Total</b>		<b>220</b>

## AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	0	0.00	0	0.00
05 - 09	0	0.00	0	0.00	0	0.00
10 - 14	0	0.00	0	0.00	0	0.00
15 - 19	0	0.00	0	0.00	0	0.00
20 - 24	0	0.00	0	0.00	0	0.00
25 - 29	0	0.00	1	1.15	1	0.45
30 - 34	1	0.75	3	3.45	4	1.82
35 - 39	6	4.51	3	3.45	9	4.09
40 - 44	8	6.02	6	6.90	14	6.36
45 - 49	10	7.52	12	13.79	22	10.00
50 - 54	10	7.52	14	16.09	24	10.91
55 - 59	13	9.77	8	9.20	21	9.55
60 - 64	21	15.79	5	5.75	26	11.82
65 - 69	16	12.03	9	10.34	25	11.36
70 - 74	19	14.29	8	9.20	27	12.27
75 - 79	13	9.77	6	6.90	19	8.64
80 - 84	11	8.27	7	8.05	18	8.18
85 - 89	2	1.50	5	5.75	7	3.18
90 - 94	3	2.26	0	0.00	3	1.36
95 +	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>133</b>	<b>100.00</b>	<b>87</b>	<b>100.00</b>	<b>220</b>	<b>100.00</b>

■ Male ■ Female



## METHOD OF DIAGNOSIS


(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Biochemical	0	0.00	0	0.00	0	0.00
Other	4	6.25	2	4.88	6	5.71
Cytology	0	0.00	0	0.00	0	0.00
Histology	60	93.75	39	95.12	99	94.29
Imaging	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>64</b>	<b>100.00</b>	<b>41</b>	<b>100.00</b>	<b>105</b>	<b>100.00</b>

Other = Previously diagnosed as Colorectal cancer from other Hospital but no documentation of diagnosis

## STAGING

(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)




Unspecified stage = Incomplete staging due to insufficient patient information

## TYPE OF TREATMENT

(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR.only	21	32.81	21	51.22	42	40.00
RT only	11	17.19	3	7.32	14	13.33
CT only	9	14.06	6	14.63	15	14.29
Intervention	0	0.00	1	2.44	1	0.95
SUR.+CT	13	20.31	8	19.51	21	20.00
SUR.+I	1	1.56	0	0.00	1	0.95
SUR.+Concurrent CT-RT	4	6.25	0	0.00	4	3.81
RT+CT	1	1.56	0	0.00	1	0.95
CT+I	1	1.56	0	0.00	1	0.95
Concurrent CT-RT	3	4.69	1	2.44	4	3.81
SUR.+CT+Concurrent CT-RT	0	0.00	1	2.44	1	0.95
<b>Total</b>	<b>64</b>	<b>100.00</b>	<b>41</b>	<b>100.00</b>	<b>105</b>	<b>100.00</b>



SUR. = Surgery


RT = External radiation therapy

CT = Chemotherapy

T = Targeted therapy

## FOLLOW UP STATUS

(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



## LUNG CANCER

Tumor site		Number
34.1	Upper lobe, lung	55
34.2	Middle lobe, lung	4
34.3	Lower lobe, lung	45
34.8	Overlapping lesion of lung	2
34.9	Lung, NOS	99
<b>Total</b>		<b>205</b>


Pathology Report		Number
M8000/3	Malignant neoplasm	35
M8010/3	Carcinoma, NOS	6
M8012/3	Large cell carcinoma, NOS	1
M8041/3	Small cell carcinoma, NOS	7
M8046/3	Non small cell carcinoma	26
M8070/3	Squamous cell carcinoma, NOS	24
M8071/3	Squamous cell carcinoma, keratinizing, NOS	1
M8140/3	Adenocarcinoma, NOS	92
M8250/3	Bronchiolo-aveolar adenocarcinoma, NOS	3
M8260/3	Papillary adenocarcinoma, NOS	4
M8310/3	Clear cell adenocarcinoma, NOS	1
M8480/3	Mucinous adenocarcinoma	1
M8490/3	Signet ring cell adenocarcinoma	2
M8560/3	Adenosquamous carcinoma	1
M9050/3	Mesothelioma, malignant	1
<b>Total</b>		<b>205</b>

LUNG CANCER

## AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	0	0.00	0	0.00
05 - 09	0	0.00	0	0.00	0	0.00
10 - 14	0	0.00	0	0.00	0	0.00
15 - 19	0	0.00	0	0.00	0	0.00
20 - 24	0	0.00	0	0.00	0	0.00
25 - 29	0	0.00	1	1.33	1	0.49
30 - 34	1	0.77	3	4.00	4	1.95
35 - 39	2	1.54	0	0.00	2	0.98
40 - 44	1	0.77	1	1.33	2	0.98
45 - 49	7	5.38	6	8.00	13	6.34
50 - 54	9	6.92	3	4.00	12	5.85
55 - 59	12	9.23	11	14.67	23	11.22
60 - 64	24	18.46	12	16.00	36	17.56
65 - 69	16	12.31	12	16.00	28	13.66
70 - 74	28	21.54	10	13.33	38	18.54
75 - 79	11	8.46	9	12.00	20	9.76
80 - 84	12	9.23	4	5.33	16	7.80
85 - 89	7	5.38	2	2.67	9	4.39
90 - 94	0	0.00	1	1.33	1	0.49
95 +	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>130</b>	<b>100.00</b>	<b>75</b>	<b>100.00</b>	<b>205</b>	<b>100.00</b>

■ Male ■ Female



## METHOD OF DIAGNOSIS


(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Biochemical	0	0.00	0	0.00	0	0.00
Other	5	7.81	0	0.00	5	5.26
Cytology	1	1.56	1	3.23	2	2.11
Histology	58	0.00	29	93.55	87	91.58
Imaging	0	90.63	1	3.23	1	1.05
<b>Total</b>	<b>64</b>	<b>100.00</b>	<b>31</b>	<b>100.00</b>	<b>95</b>	<b>100.00</b>

Other = Previously diagnosed as Lung cancer from other Hospital but no documentation of diagnosis

## STAGING

(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)




Unspecified stage = Incomplete staging due to insufficient patient information

## TYPE OF TREATMENT

(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)


Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR.only	5	7.94	5	16.13	10	10.53
RT only	38	60.32	10	32.26	48	50.53
CT only	5	7.94	1	3.23	6	6.32
Targeted therapy	2	3.17	4	12.90	6	6.32
Concurrent CT-RT	5	7.94	1	3.23	6	6.32
SUR.+RT	0	0.00	1	3.23	1	1.05
SUR.+CT	0	0.00	1	3.23	1	1.05
SUR.+Concurrent CT-RT	1	1.59	0	0.00	1	1.05
RT+CT	2	3.17	0	0.00	2	2.11
RT+T	1	1.59	5	16.13	6	6.32
CT+T	1	1.59	0	0.00	1	1.05
Concurrent CT-RT+RT	1	1.59	1	3.23	2	2.11
Concurrent CT-RT+CT	1	1.59	0	0.00	1	1.05
SUR.+CT+Concurrent CT-RT	1	1.59	0	0.00	1	1.05
SUR.+Concurrent CT-RT+T	0	0.00	0	0.00	2	2.11
SUR.+RT+CT	0	0.00	2	6.45	1	1.05
<b>Total</b>	<b>63</b>	<b>100.00</b>	<b>31</b>	<b>100.00</b>	<b>95</b>	<b>100.00</b>



SUR. = Surgery  
 RT = External radiation therapy  
 CT = Chemotherapy  
 T = Targeted therapy

## FOLLOW UP STATUS

(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)






## LIVER & HEPATOBILIARY CANCER

Tumor site		Number
C22.0	Liver	110
C22.1	Liver (Pathology is M8160/3)	23
C23.9	Gall bladder	6
C24.0	Common bile duct	3
C24.1	Ampullar of vater	8
<b>Total</b>		<b>150</b>

Pathology Report		Number
M8000/3	Malignant neoplasm	87
M8010/3	Carcinoma, NOS	1
M8022/3	Pleomorphic carcinoma	1
M8140/3	Adenocarcinoma, NOS	15
M8160/3	Cholangiocarcinoma	11
M8170/3	Hepatocellular carcinoma, NOS	29
M8246/3	Neuroendocrine carcinoma, NOS	2
M8260/3	Papillary adenocarcinoma	2
M8480/3	Mucinous adenocarcinoma	1
M8490/3	Signet ring cell carcinoma	1
<b>Total</b>		<b>150</b>

## PATHOLOGY REPORT OF HEPATOBILIARY CANCER




*Malignant neoplasm = Dx. For Cancer but unknown special type*

## AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	0	0.00	0	0.00
05 - 09	0	0.00	0	0.00	0	0.00
10 - 14	0	0.00	0	0.00	0	0.00
15 - 19	0	0.00	0	0.00	0	0.00
20 - 24	0	0.00	0	0.00	0	0.00
25 - 29	0	0.00	0	0.00	0	0.00
30 - 34	2	1.90	0	0.00	2	1.33
35 - 39	4	3.81	1	2.22	5	3.33
40 - 44	5	4.76	3	6.67	8	5.33
45 - 49	5	4.76	1	2.22	6	4.00
50 - 54	12	11.43	2	4.44	14	9.33
55 - 59	15	14.29	8	17.78	23	15.33
60 - 64	19	18.10	5	11.11	24	16.00
65 - 69	18	17.14	10	22.22	28	18.67
70 - 74	10	9.52	9	20.00	19	12.67
75 - 79	8	7.62	3	6.67	11	7.33
80 - 84	5	4.76	3	6.67	8	5.33
85 - 89	1	0.95	0	0.00	1	0.67
90 - 94	1	0.95	0	0.00	1	0.67
95 +	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>105</b>	<b>100.00</b>	<b>45</b>	<b>100.00</b>	<b>150</b>	<b>100.00</b>



■ Male ■ Female



## METHOD OF DIAGNOSIS


(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Biochemical	3	6.25	0	0.00	3	4.55
Other	0	0.00	0	0.00	0	0.00
Cytology	0	0.00	0	0.00	0	0.00
Histology	25	52.08	10	55.56	35	53.03
Imaging	20	41.67	8	44.44	28	42.42
<b>Total</b>	<b>48</b>	<b>100.00</b>	<b>18</b>	<b>100.00</b>	<b>66</b>	<b>100.00</b>




## STAGING

(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



### Hepatoma only




Unspecified stage = Incomplete staging due to insufficient patient information

## TYPE OF TREATMENT

(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)


Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR.only	6	12.50	3	16.67	9	13.64
RT only	1	2.08	0	0.00	1	1.52
CT only	4	8.33	1	5.56	5	7.58
Targeted therapy	1	2.08	1	5.56	2	3.03
Intervention	30	62.50	12	66.67	42	63.64
SUR.+CT	1	2.08	1	5.56	2	3.03
SUR.+I	1	2.08	0	0.00	1	1.52
RT+I	1	2.08	0	0.00	1	1.52
I+T	3	6.25	0	0.00	3	4.55
<b>Total</b>	<b>48</b>	<b>100.00</b>	<b>18</b>	<b>100.00</b>	<b>66</b>	<b>100.00</b>



SUR. = Surgery  
 RT = External radiation therapy  
 CT = Chemotherapy  
 T = Targeted therapy  
 I = Intervention



TYPE OF TREATMENT IN HEPATOMA CANCER  
(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR.only	2	5.56	1	7.14	3	6.00
Targeted therapy	0	0.00	1	7.14	1	2.00
Intervention	30	83.33	12	85.71	42	84.00
RT+I	1	2.78	0	0.00	1	2.00
I+T	3	8.33	0	0.00	3	6.00
<b>Total</b>	<b>36</b>	<b>100.00</b>	<b>14</b>	<b>100.00</b>	<b>50</b>	<b>100.00</b>



SUR. = Surgery  
RT = External radiation therapy  
I = Intervention  
T = Targeted therapy

FOLLOW UP STATUS  
(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



## HEAD & NECK CANCER


Tumor site		Number
C00.1	Lower lip	1
C01.9	Base of tongue, NOS	10
C02.1	Border of tongue	2
C02.9	Tongue	24
C03.0	Upper gum	1
C04.9	Floor of mouth	3
C05.0	Hard palate	2
C06.0	Cheek mucosa	9
C06.2	Retromolar area	1
C06.9	Mouth, NOS	3
C07.9	Parotid gland	4
C08.0	Submandibular gland	1
C08.9	Major salivary gland	3
C09.9	Tonsil, NOS	8
C10.9	Oropharynx, NOS	1
C11.2	Lateral wall of nasopharynx	1
C11.9	Nasopharynx, NOS	36
C12.9	Pyriform sinus	4
C13.0	Postcricoid region	1
C13.9	Hypopharynx, NOS	1
C14.0	Pharynx, NOS	1
<b>Total</b>		<b>117</b>

Pathology Report		Number
M8000/3	Malignant neoplasm	23
M8010/3	Carcinoma, NOS	1
M8020/3	Carcinoma, undifferentiated, NOS	10
M8051/3	Verrucous carcinoma, NOS	2
M8070/3	Squamous cell carcinoma, NOS	58
M8071/3	Squamous cell carcinoma, keratinizing, NOS	6
M8072/3	Squamous cell carcinoma, large cell, nonkeratinizing, NOS	8
M8200/3	Adenoid cystic carcinoma	6
M8410/3	Sebaceous adenocarcinoma	1
M8430/3	Mucoepidermoid carcinoma	1
M8560/3	Adenosquamous carcinoma	1
<b>Total</b>		<b>117</b>

## AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	0	0.00	0	0.00
05 - 09	0	0.00	0	0.00	0	0.00
10 - 14	0	0.00	0	0.00	0	0.00
15 - 19	0	0.00	1	3.03	1	0.85
20 - 24	0	0.00	0	0.00	0	0.00
25 - 29	1	1.19	1	3.03	2	1.71
30 - 34	1	1.19	4	12.12	5	4.27
35 - 39	1	1.19	2	6.06	3	2.56
40 - 44	7	8.33	2	6.06	9	7.69
45 - 49	10	11.90	5	15.15	15	12.82
50 - 54	10	11.90	3	9.09	13	11.11
55 - 59	11	13.10	7	21.21	18	15.38
60 - 64	23	27.38	1	3.03	24	20.51
65 - 69	9	10.71	2	6.06	11	9.40
70 - 74	3	3.57	2	6.06	5	4.27
75 - 79	4	4.76	2	6.06	6	5.13
80 - 84	4	4.76	1	3.03	5	4.27
85 - 89	0	0.00	0	0.00	0	0.00
90 - 94	0	0.00	0	0.00	0	0.00
95 +	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>84</b>	<b>100.00</b>	<b>33</b>	<b>100.00</b>	<b>117</b>	<b>100.00</b>

■ Male ■ Female



## METHOD OF DIAGNOSIS


(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Biochemical	0	0.00	0	0.00	0	0.00
Other	4	8.00	1	4.35	5	6.85
Cytology	0	0.00	0	0.00	0	0.00
Histology	46	92.00	22	95.65	68	93.15
Imaging	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>50</b>	<b>100.00</b>	<b>23</b>	<b>100.00</b>	<b>73</b>	<b>100.00</b>

Other = Previously diagnosed as Head & Neck cancer from other Hospital but no document of Pathology

## STAGING

(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)




Unspecified stage = Incomplete staging due to insufficient patient information

## TYPE OF TREATMENT

(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
SUR.only	9	18.00	3	13.04	12	16.44
RT only	19	38.00	10	43.48	29	39.73
CT only	2	4.00	0	0.00	2	2.74
Concurrent CT-RT	9	18.00	4	17.39	13	17.81
SUR.+RT	3	6.00	2	8.70	5	6.85
SUR.+Concurrent CT-RT	6	12.00	1	4.35	7	9.59
Concurrent CT-RT+RT	1	2.00	0	0.00	1	1.37
Concurrent CT-RT+CT	0	0.00	3	13.04	3	4.11
SUR.+RT+CT	1	2.00	0	0.00	1	1.37
<b>Total</b>	<b>50</b>	<b>100.00</b>	<b>23</b>	<b>100.00</b>	<b>73</b>	<b>100.00</b>



SUR. = Surgery


RT = External radiation therapy

CT = Chemotherapy

T = Targeted therapy

## FOLLOW UP STATUS

(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)




# HEMATOLOGIC MALIGNANCIES 2015

## DISTRIBUTION OF HEMATOLOGIC MALIGNANCIES

Code	Disease	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
C81	Hodgkin's disease	8	7.21	5	10.42	13	8.18
C82	Follicular NHL	8	7.21	4	8.33	12	7.55
C83	Diffuse NHL	30	27.03	13	27.08	43	27.04
C84	Peripheral and cutaneous T-cell lymphoma	7	6.31	1	2.08	8	5.03
C85	Other and unspecified type of NHL	10	9.01	3	6.25	13	8.18
C90	Multiple myeloma	16	14.41	8	16.67	24	15.09
C91	Lymphoid leukemia	13	11.71	9	18.75	22	13.84
C92	Myeloid leukemia	18	16.22	5	10.42	23	14.47
C93	Monocytic leukemia	1	0.90	0	0.00	1	0.63
<b>Total</b>		<b>111</b>	<b>100.00</b>	<b>48</b>	<b>100.00</b>	<b>159</b>	<b>100.00</b>

### All patient




## DISTRIBUTION OF HEMATOLOGIC MALIGNANCIES

### BY AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	0	0.00	0	0.00
05 - 09	2	1.80	2	4.17	4	2.52
10 - 14	2	1.80	0	0.00	2	1.26
15 - 19	5	4.50	1	2.08	6	3.77
20 - 24	3	2.70	0	0.00	3	1.89
25 - 29	4	3.60	4	8.33	8	5.03
30 - 34	12	10.81	1	2.08	13	8.18
35 - 39	4	3.60	3	6.25	7	4.40
40 - 44	7	6.31	3	6.25	10	6.29
45 - 49	12	10.81	7	14.58	19	11.95
50 - 54	11	9.91	3	6.25	14	8.81
55 - 59	7	6.31	9	18.75	16	10.06
60 - 64	12	10.81	1	2.08	13	8.18
65 - 69	9	8.11	3	6.25	12	7.55
70 - 74	8	7.21	2	4.17	10	6.29
75 - 79	9	8.11	4	8.33	13	8.18
80 - 84	2	1.80	3	6.25	5	3.14
85 - 89	0	0.00	2	4.17	2	1.26
90 - 94	1	0.90	0	0.00	1	0.63
95 +	1	0.90	0	0.00	1	0.63
<b>Total</b>	<b>111</b>	<b>100.00</b>	<b>48</b>	<b>100.00</b>	<b>159</b>	<b>100</b>

### Male Female




OVERALL HEMATOLOGIC MALIGNANCIES




## PATIENT NATIONALITY

Patient Nationality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Thai	37	27.21	22	95.65	59	37.11
Non-Thai	99	72.79	1	4.35	100	62.89
<b>Total</b>	<b>136</b>	<b>100.00</b>	<b>23</b>	<b>100.00</b>	<b>159</b>	<b>100.00</b>



## PATIENT FOLLOW UP STATUS




## LYMPHOMA


### AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	0	0.00	0	0.00
05 - 09	2	3.28	0	0.00	2	2.25
10 - 14	2	3.28	0	0.00	2	2.25
15 - 19	2	3.28	1	3.57	3	3.37
20 - 24	2	3.28	0	0.00	2	2.25
25 - 29	0	0.00	2	7.14	2	2.25
30 - 34	9	14.75	1	3.57	10	11.24
35 - 39	2	3.28	3	10.71	5	5.62
40 - 44	2	3.28	2	7.14	4	4.49
45 - 49	6	9.84	4	14.29	10	11.24
50 - 54	6	9.84	2	7.14	8	8.99
55 - 59	6	9.84	6	21.43	12	13.48
60 - 64	7	11.48	1	3.57	8	8.99
65 - 69	3	4.92	0	0.00	3	3.37
70 - 74	6	9.84	1	3.57	7	7.87
75 - 79	5	8.20	2	7.14	7	7.87
80 - 84	1	1.64	1	3.57	2	2.25
85 - 89	0	0.00	0	0.00	0	0.00
90 - 94	0	0.00	1	3.57	1	1.12
95 +	0	0.00	1	3.57	1	1.12
<b>Total</b>	<b>61</b>	<b>100.00</b>	<b>28</b>	<b>100.00</b>	<b>89</b>	<b>100</b>

■ Male ■ Female



Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
< 15 yr.	4	6.56	0	0.00	4	4.49
≥ 15 yr.	57	93.44	28	100.00	85	95.51
<b>Total</b>	<b>61</b>	<b>100.00</b>	<b>28</b>	<b>100.00</b>	<b>89</b>	<b>100.00</b>




## METHOD OF DIAGNOSIS

(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Histology	16	72.73	6	85.71	22	75.86
Histology + Flow cytometry	4	18.18	0	0.00	4	13.79
Histology + Immunohistochemistry	1	4.55	1	14.29	2	6.90
Histology + Flow cytometry + Immunohistochemistry	1	4.55	0	0.00	1	3.45
<b>Total</b>	<b>22</b>	<b>100.00</b>	<b>7</b>	<b>100.00</b>	<b>29</b>	<b>100.00</b>

## STAGING

(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)




Unspecified stage = Incomplete staging due to insufficient patient information

## TYPE OF TREATMENT

(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)


Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	0	0.00	1	14.29	1	3.45
Radiotherapy	3	13.64	3	42.86	6	20.69
Chemotherapy	14	63.64	1	14.29	15	51.72
Targeted therapy	1	4.55	0	0.00	1	3.45
Surgery + Chemotherapy	2	9.09	0	0.00	2	6.90
Chemotherapy + Radiotherapy	1	4.55	2	28.57	3	10.34
Chemotherapy + Bone Marrow Transplantation	1	4.55	0	0.00	1	3.45
<b>Total</b>	<b>22</b>	<b>100.00</b>	<b>7</b>	<b>100.00</b>	<b>29</b>	<b>100.00</b>



## PATIENT FOLLOW UP STATUS

(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive with disease	15	68.18	6	85.71	21	72.41
Alive without disease	4	18.18	0	0.00	4	13.79
Dead with disease	3	13.64	1	14.29	4	13.79
<b>Total</b>	<b>22</b>	<b>100.00</b>	<b>7</b>	<b>100.00</b>	<b>29</b>	<b>100.00</b>




# MULTIPLE MYELOMA


## AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	0	0.00	0	0.00
05 - 09	0	0.00	0	0.00	0	0.00
10 - 14	0	0.00	0	0.00	0	0.00
15 - 19	0	0.00	0	0.00	0	0.00
20 - 24	0	0.00	0	0.00	0	0.00
25 - 29	0	0.00	0	0.00	0	0.00
30 - 34	0	0.00	0	0.00	0	0.00
35 - 39	0	0.00	0	0.00	0	0.00
40 - 44	1	6.25	0	0.00	1	4.17
45 - 49	1	6.25	2	25.00	3	12.50
50 - 54	2	12.50	0	0.00	2	8.33
55 - 59	1	6.25	1	12.50	2	8.33
60 - 64	1	6.25	0	0.00	1	4.17
65 - 69	5	31.25	1	12.50	6	25.00
70 - 74	1	6.25	0	0.00	1	4.17
75 - 79	3	18.75	1	12.50	4	16.67
80 - 84	1	6.25	2	25.00	3	12.50
85 - 89	0	0.00	1	12.50	1	4.17
90 - 94	0	0.00	0	0.00	0	0.00
95 +	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>16</b>	<b>100.00</b>	<b>8</b>	<b>100.00</b>	<b>24</b>	<b>100.00</b>

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
< 15 yr.	0	0.00	0	0.00	0	0.00
≥ 15 yr.	16	100.00	8	100.00	24	100.00
<b>Total</b>	<b>16</b>	<b>100.00</b>	<b>8</b>	<b>100.00</b>	<b>24</b>	<b>100.00</b>



■ Male ■ Female



## METHOD OF DIAGNOSIS


(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Histology	2	40.00	1	33.33	3	37.50
Histology + Flow cytometry	1	20.00	2	66.67	3	37.50
Histology + Immunohistochemistry	1	20.00	0	0.00	1	12.50
Histology + Flow cytometry + Immunohistochemistry	1	20.00	0	0.00	1	12.50
<b>Total</b>	<b>5</b>	<b>100.00</b>	<b>3</b>	<b>100.00</b>	<b>8</b>	<b>100.00</b>

## TYPE OF TREATMENT

(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)


Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiotherapy	1	20.00	0	0.00	1	12.50
Chemotherapy	2	40.00	1	33.33	3	37.50
Targeted therapy	0	0.00	1	33.33	1	12.50
Chemotherapy + Radiotherapy	1	20.00	0	0.00	1	12.50
Chemotherapy + Bone Marrow Transplantation	1	20.00	1	33.33	2	25.00
<b>Total</b>	<b>5</b>	<b>100.00</b>	<b>3</b>	<b>100.00</b>	<b>8</b>	<b>100.00</b>



## PATIENT FOLLOW UP STATUS

(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive with disease	4	80.00	2	66.67	6	75.00
Alive without disease	1	20.00	0	0.00	1	12.50
Dead with disease	0	0.00	1	33.33	1	12.50
<b>Total</b>	<b>5</b>	<b>100.00</b>	<b>3</b>	<b>100.00</b>	<b>8</b>	<b>100.00</b>




# LEUKEMIA


## AGE AND GENDER

Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 04	0	0.00	0	0.00	0	0.00
05 - 09	0	0.00	2	14.29	2	4.35
10 - 14	0	0.00	0	0.00	0	0.00
15 - 19	3	9.38	0	0.00	3	6.52
20 - 24	1	3.13	0	0.00	1	2.17
25 - 29	4	12.50	2	14.29	6	13.04
30 - 34	3	9.38	0	0.00	3	6.52
35 - 39	2	6.25	0	0.00	2	4.35
40 - 44	3	9.38	1	7.14	4	8.70
45 - 49	4	12.50	1	7.14	5	10.87
50 - 54	3	9.38	1	7.14	4	8.70
55 - 59	0	0.00	2	14.29	2	4.35
60 - 64	4	12.50	0	0.00	4	8.70
65 - 69	2	6.25	2	14.29	4	8.70
70 - 74	1	3.13	1	7.14	2	4.35
75 - 79	2	6.25	1	7.14	3	6.52
80 - 84	0	0.00	0	0.00	0	0.00
85 - 89	0	0.00	1	7.14	1	2.17
90 - 94	0	0.00	0	0.00	0	0.00
95 +	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>32</b>	<b>100.00</b>	<b>14</b>	<b>100.00</b>	<b>46</b>	<b>100.00</b>

■ Male ■ Female



Age	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
< 15 yr.	0	0.00	2	14.29	2	4.35
≥ 15 yr.	32	100.00	12	85.71	44	95.65
<b>Total</b>	<b>32</b>	<b>100.00</b>	<b>14</b>	<b>100.00</b>	<b>46</b>	<b>100.00</b>



LEUKEMIA

## METHOD OF DIAGNOSIS


(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Histology	4	36.36	0	0.00	4	25.00
Histology + Flow cytometry	4	36.36	5	100.00	9	56.25
Histology + Chromosome	1	9.09	0	0.00	1	6.25
Histology + Peripheral blood smear	1	9.09	0	0.00	1	6.25
Histology + Flow cytometry + Peripheral blood smea	1	9.09	0	0.00	1	6.25
<b>Total</b>	<b>11</b>	<b>100.00</b>	<b>5</b>	<b>100.00</b>	<b>16</b>	<b>100.00</b>

## TYPE OF TREATMENT

(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)


Management of treatment	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiotherapy	1	9.09	0	0.00	1	6.25
Chemotherapy	7	63.64	3	60.00	10	62.50
Chemotherapy + Bone Marrow Transplantation	3	27.27	2	40.00	5	31.25
<b>Total</b>	<b>11</b>	<b>100.00</b>	<b>5</b>	<b>100.00</b>	<b>16</b>	<b>100.00</b>



## PATIENT FOLLOW UP STATUS

(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive with disease	11	100.00	4	80.00	15	93.75
Alive without disease	0	0.00	1	20.00	1	6.25
<b>Total</b>	<b>11</b>	<b>100.00</b>	<b>5</b>	<b>100.00</b>	<b>16</b>	<b>100.00</b>







AGE DISTRIBUTION IN ALL FEMALE CANCER NUMBERS OF CASE  
(INCLUDED HEMATOLOGIC MALIGNANCIES)

Code	Primary site	Age Group																		Total	%							
		00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89			90-95	95+					
C00	Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00	
C01-C02	Tongue	0	0	0	0	0	0	0	0	0	0	1	1	5	0	1	0	0	0	0	0	0	0	0	0	0	0.83	
C03	Gum	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0.09	
C04	Floor of mouth	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00	
C05	Palate	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0.09	
C06	Other part of mouth	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	4	0.37	
C07	Parotid gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.09	
C08	Other and unspecified major salivary glands	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00	
C09	Tonsil	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.09	
C10	Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00	
C11-C14	Head and Neck	0	0	0	1	0	0	0	3	2	1	4	1	2	0	1	0	0	0	0	0	0	0	0	0	0	16	1.48
C15	Esophagus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	3	0.28
C16	Stomach	0	0	0	0	0	1	1	2	4	1	1	5	1	0	2	1	0	1	0	0	0	0	0	0	22	2.04	
C17	Small intestine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00	
C18-C20	Colon and Rectum	0	0	0	0	0	1	3	3	6	12	14	8	5	9	8	6	7	5	0	0	0	0	0	0	87	8.06	
C21	Anus	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	1	0	0	0	0	1	0	0	5	0.46	
C22-C24	Liver and Hepatobiliary	0	0	0	0	0	0	0	0	0	1	3	1	2	8	5	10	9	3	3	0	0	0	0	0	45	4.17	
C25	Pancreas	0	0	0	0	0	0	0	0	0	0	2	1	4	7	1	2	2	1	1	2	0	0	0	0	24	2.22	
C26	Other and ill-defined digestive organ	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00	
C30	Nasal cavity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	2	0.19	
C31	Accessory sinuses	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	1	0	0	0	0	0	0	0	0	4	0.37	
C32	Larynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0.19	
C33-C34	Lung	0	0	0	0	0	1	3	0	1	6	3	11	12	12	10	9	4	2	1	0	0	0	0	0	75	6.95	
C37	Thymus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00	
C38	Mediastinum	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00	
C40-C41	Bone	0	0	0	0	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0.19	
C43-C44	Skin	0	0	0	0	0	0	1	0	1	1	2	2	1	4	0	1	2	0	1	1	2	0	1	2	19	1.76	
C47	Sacral nerve	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.09	
C48	Retroperitoneum	0	0	0	0	0	0	0	0	0	0	0	0	1	3	0	1	0	0	0	0	0	0	0	0	5	0.46	
C49	Connective tissue	0	0	0	0	1	1	1	1	1	1	1	3	2	1	0	0	0	0	0	0	0	0	0	0	13	1.20	

Code	Primary site	Age Group																		Total	%						
		00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89			90-95	95+				
C50	Breast	0	0	0	0	0	2	6	20	46	73	71	72	52	31	19	8	1	5	0	0	0	0	0	406	37.63	
C51	Vulva	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0.19
C52	Vagina	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C53	Cervix	0	0	0	0	0	4	2	10	2	5	12	13	5	4	4	2	0	0	0	1	0	0	0	64	5.93	
C54	Corpus uteri	0	0	0	0	1	3	2	2	2	2	5	6	10	6	2	3	1	0	0	0	0	0	0	47	4.36	
C55	Uterus	0	0	0	0	0	0	0	1	3	6	6	8	6	5	0	2	0	0	0	0	0	0	0	6	0.56	
C56	Ovary	0	0	0	0	0	0	1	1	3	6	6	8	6	5	0	2	0	0	0	0	0	0	0	38	3.52	
C57	Other female genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C58	Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C60	Penis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C61	Prostate gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C62	Testis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C63	Other and unspecified male genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C64-C65	Urinary tract	0	0	0	0	0	1	0	0	1	1	0	0	1	2	0	1	2	0	0	0	0	0	0	9	0.83	
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C67	Bladder	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	0	0	0	0	0	1	0	0	5	0.46	
C68	Urinary organ unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C69	Eye and Adnexa	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.09	
C70-C71	Brain	0	1	0	0	0	0	0	0	0	2	0	1	2	0	1	1	0	0	0	0	0	0	0	11	1.02	
C72	Spinal cord and CNS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C73	Thyroid gland	0	0	0	1	3	6	5	6	10	5	7	5	4	3	1	1	0	0	0	0	0	0	0	57	5.28	
C74	Adrenal gland	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2	0.19	
C75	Other and endocrine gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C76	Other and ill-defined	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00
C79	Unknown primary site	0	0	0	0	0	1	0	0	0	1	0	0	0	0	1	2	0	0	0	0	0	0	0	9	0.83	
C81	Hodgkin's disease	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	5	0.46	
C82	Follicular NHL	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	1	0	0	0	0	0	0	0	4	0.37	
C83	Diffuse NHL	0	0	0	0	0	1	0	0	0	2	2	5	1	0	1	0	1	0	0	0	0	0	0	13	1.20	
C84	Peripheral and cutaneous T-cell lymphoma	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.09	
C85	Other and unspecified type of NHL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	0.28	
C90	Multiple myeloma	0	0	0	0	0	0	1	0	0	0	1	0	1	0	0	1	0	0	0	0	0	0	0	8	0.74	
C91	Lymphoid leukemia	0	2	0	0	0	2	0	0	0	0	0	1	0	2	1	1	0	0	0	0	0	0	0	9	0.83	
C92	Myeloid leukemia	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	1	0	0	0	0	0	5	0.46	
D05	Ductal carcinoma in situ of breast	0	0	0	0	0	1	0	4	4	6	6	4	2	2	2	1	0	0	0	0	0	0	0	32	2.97	
	All ICD Group	1	4	0	3	5	27	32	60	94	1																

## A Report on Cancer Survival in Wattanosoth Cancer Hospital

This report on cancer survival is based on an analysis of data of top 3 common cancers (i.e., breast, colorectal and lung cancer) in Wattanosoth Cancer Hospital (WSH). The data has been collected by the hospital tumor registry. The cancer patients were diagnosed during a 12 month period from January 1 to December 31, 2010. All of them received treatment at WSH and were prospectively followed-up up to December 31, 2016 (5 year follow-up period).

Survival rates were estimated by Kaplan-Meier method. The survival rates of subgroups of cancer patients categorized by age (aged  $\leq 50$  and  $> 50$  years old), sex (male and female) and stage of cancer at diagnosis (stage 0 - 4) were analyzed for comparison.

As this report is hospital registry-based cancer survival analysis, the study may have limitations related to endpoint data and sample size. The observed survival rates are estimated by method which cumulative probability of survival is calculated at consecutive one month intervals after diagnosis. The information used included death from the cancer and other causes; lost to follow-up before observation period ended; and follow-up ends due to observation period ended. Therefore survival estimated may be biased if the proportion of lost to follow-up or other causes of death is high. Survival rate estimated from small numbers of cases can provide misleading results and may have wide confidence intervals. In addition to compare survival rate between different groups, test for statistical significant may be misleading.

## Breast Cancer Survival

126 cases were diagnosed breast cancer during January 1 to December 31, 2010. At the time of diagnosis, 38 (28.8%) of them were at stage 1, 53 (40.2%) at stage 2, 21 (15.9%) at stage 3, and 20 (15.1%) at stage 4. Their average age was 52.9 years old (SD  $\pm 11.7$ ). 57 (41.3%) of them aged  $\leq 50$  years old and 81 (58.7%) aged  $> 50$  years old.


The median follow-up period of these breast cancer patients was 54.5 months (25<sup>th</sup> - 75<sup>th</sup> percentile: 7 - 60 months). During the 5 year follow-up period, 8 of them were dead and 0 were lost to follow-up.

The overall observed survival rate of the breast cancer patients at 5 year follow-up period was 91.4% (95% CI: 83.4 - 95.7) (Fig.1). The survival seems to have no difference between the age group of  $> 50$  and  $\leq 50$  years old, of which the survival rate was 89.5% (95% CI: 77.8 - 95.3), and 94.3% (95% CI: 79.2 - 98.6) respectively (Fig. 2).


The observed survival of the early stage breast cancers, i.e., stage 1 and 2 was 100% respectively, while the survival of the late stages, i.e., stage 3 and 4 was 81.8% (95% CI: 44.7 to 95.1) and 46.5% (95% CI: 16.3 to 72.5) respectively (Fig. 3). The survival rate tends to be lower in the late stage breast cancers.



**Figure 1.** Overall observed survival rate of the breast cancer patients in WSH during 5 year follow-up period



**Figure 2.** Observed survival rate of the breast cancer patients in WSH during 5 year follow-up period by age group of ≤ 50 and > 50 years old



**Figure 3.** Observed survival rate of the breast cancer patients in WSH during 5 year follow-up period by stage of the cancer at diagnosis (stage 0 - 4)

## Colorectal Cancer Survival

67 cases were diagnosed colorectal cancer during January 1 to December 31, 2010. At the time of diagnosis, 10 (14.9%) of them were at stage 1, 16 (23.9%) at stage 2, 25 (37.3%) at stage 3, and 14 (20.9%) at stage 4. Their average age was 64.2 years old (SD ± 14.4). 8 (11.9%) of them aged ≤ 50 years old and 59 (88.1%) aged > 50 years old. Among of them, there were 38 (56.7%) males and 29 (43.3%) females.


The median follow-up period of these colorectal cancer patients was 27 months (25<sup>th</sup> - 75<sup>th</sup> percentile: 8 - 60 months). During the 5 year follow-up period, 7 of them were dead and 1 were lost to follow-up.

The overall observed survival rate of the colorectal cancer patients at 5 year follow-up period was 82.3% (95% CI: 65.6 - 91.4) (Fig. 1). The survival among the male patients was 76.8% (95% CI: 50.9 - 90.2) and female was 88.7% (95% CI: 61.4 - 97.1) (Fig. 2). The female patients seem to have lower observed survival rate. The survival seems to have no difference between the age group of > 50 and ≤ 50 years old, of which the survival rate was 80.2% (95% CI: 62.1 - 90.3) and 100.0% respectively (Fig. 3).


The observed survival of early stage colorectal cancers, i.e., stage 1 and 2 was 100.0% and 77.1% (95% CI: 34.5 - 93.9) respectively, while the survival of the late stages, i.e., stage 3 and 4 was 87.3% (95% CI: 56.4 - 96.8) and 37.5% (95% CI: 1.4 - 79.9) respectively (Fig. 4). The observed survival tends to be decreased as the cancer stage advanced. Especially in the stage 4, the survival was substantially decreased.




**Figure 1.** Overall observed survival rate of the colorectal cancer patients in WSH during 5 year follow-up period



**Figure 2.** Observed survival rate of the colorectal cancer patients in WSH during 5 year follow-up period by gender (male and female)



**Figure 4.** Observed survival rate of the colorectal cancer patients in WSH during 5 year follow-up period by stage of the cancer at diagnosis (stage 1 - 4)



**Figure 3.** Observed survival rate of the colorectal cancer patients in WSH during 5 year follow-up period by age group of ≤ 50 and > 50 years old

## Lung Cancer Survival

73 cases were diagnosed lung cancer during January 1 to December 31, 2010. At the time of diagnosis, 12 (16.4%) of them were at stage 1, 7 (9.6%) at stage 2, 16 (21.9%) at stage 3, and 36 (49.3%) at stage 4. Their average age was 60.2 years old (SD ± 13.5). 17 (23.3%) of them aged ≤ 50 years old and 59 (76.7%) aged > 50 years old. Among of them, there were 45 (61.6%) males and 28 (38.4%) females.


The median follow-up period of these lung cancer patients was 9 months (25<sup>th</sup> - 75<sup>th</sup> percentile: 3 - 27). During the 5 year follow-up period, 20 of them were dead and 1 were lost to follow-up.

The observed survival rate of the lung cancer patients at 5 year follow-up period was 34.7% (95% CI: 13.8 - 56.7) (Fig. 1). The survival seems to have no difference between male and female patients, of which the survival rate was 43.5% (95% CI: 15.2 - 69.2) and 21.1% (95% CI: 1.5 - 56.2) respectively (Fig. 2). The survival of patients aged > 50 and ≤ 50 years old was 32.0% (95% CI: 9.8 - 57.1) and 44.8% (95% CI: 8.5 - 76.9) respectively (Fig. 3). The patients aged > 50 years old seem to have lower observed survival rate.


The observed survival rate of early stage lung cancers, i.e., stage 1 and 2 was 66.7 (95% CI: 5.4 - 94.5) and 50.0 (95% CI: 11.1 - 80.4) respectively while the survival of late stages, i.e., stage 3 and 4 was 50.9 (95% CI: 7.9 - 83.5) and 23.4 (95% CI: 1.7 - 59.8) respectively (Fig. 4). The observed survival tends to be decreased as the cancer stage advanced.




**Figure 1.** Overall observed survival rate of the lung cancer patients in WSH during 5 year follow-up period



**Figure 2.** Observed survival rate of the lung cancer patients in WSH during 5 year follow-up period by gender (male and female)



**Figure 3.** Observed survival rate of the lung cancer patients in WSH during 5 year follow-up period by age group of ≤ 50 and > 50 years old




**Figure 4.** Observed survival rate of the lung cancer patients in WSH during 5 year follow-up period by stage of the cancer at diagnosis (stage 1 - 4)

## Cancer Registry


### Team



Komgrit Tanisaro  
M.D.



Natthaphum Khanchanaporn  
M.D.



Surachai Sitawarin  
M.D.



Saengduan Chindavijak  
M.D.



Waraphorn Chomphu  
Tumor Registered-Officer (WSH)



Pichet Pariyarungsi  
Senior Business Intelligence Manager